Siemens Healthineers Faces Twin Tests: Fourth-Quarter Delivery and the Lab-Diagnostics Question
Published on 11/03/2026 at 16:31 | Editorial boerse-global.de
Siemens Healthineers will publish figures for its fourth quarter and the full 2025/26 fiscal year on November 5, 2026, and the market has two separate matters to weigh. One is whether the closing quarter delivers the acceleration analysts expect. The other is whether management finally sheds light on the future of its laboratory diagnostics unit, a spin-off of which has not yet been decided.
Consensus looks for comparable revenue growth of 5.5% in the final quarter, with sales of EUR 6.7 billion against EUR 6.3 billion a year earlier. That sets a demanding bar for the year-end, and the pressure in diagnostics — where the China business and expiring systems are weighing on performance — will be central to whether the company clears it.
For the full year, analysts project revenue of roughly EUR 23.6 billion, adjusted earnings before interest and taxes of EUR 3.85 billion and adjusted earnings per share of EUR 2.39. These are estimates rather than reported results, and they form the yardstick for Thursday's release. On EPS, the consensus sits inside the company's own guidance range: Siemens Healthineers has guided to comparable revenue growth of 3.5–4.0% for 2025/26 and adjusted EPS of EUR 2.35 to 2.45.
Buyback Runs Alongside, Not Instead Of, Operational Progress
The reporting date comes against a backdrop of share purchases. In a disclosure published yesterday, the company said it bought 50,000 of its own shares in the past week, taking the total since the programme began on June 1 to 3,629,346 shares. All transactions went through XETRA. The stock rose 1.8% yesterday, extending a recovery — but the buyback is a supporting capital measure, not evidence that pressures in the business have eased.
Should investors sell immediately? Or is it worth buying Siemens Healthineers?
That distinction matters because the operational picture remains mixed. Bernstein Research cut its price target to EUR 44.50 from EUR 45.70 on August 4 while keeping its "Outperform" rating. Analyst Susannah Ludwig pointed to problems in the Chinese diagnostics business, which triggered another cut to guidance, but she also flagged strength in the order book in the core business. Her view was no blanket rejection of the company's prospects; it separated robust demand in the core from the difficulties in diagnostics.
Two Structural Questions, Not One
A potential spin-off of the diagnostics division and the planned reduction of Siemens' stake are distinct projects. For Healthineers, the diagnostics question concerns how the company itself will be configured. The Siemens plans concern the parent's holding. According to media reports, implementing a diagnostics separation could take about 24 months after a decision. Shareholder votes on the separate Healthineers carve-out by Siemens are planned for 2027, with an initial 30% stake sale envisaged.
November 5 is therefore not automatically a decision date for diagnostics. Absent a resolution, a separation remains a strategic option rather than a settled restructuring — though clearer guidance on the way forward would help investors frame the longer-term business.
Siemens Healthineers at a turning point? This analysis reveals what investors need to know now.
Earnings Already Show Improvement
The third quarter of fiscal 2026 offered a reminder that reported performance and guidance can point in different directions. EPS came in at EUR 0.60, up from EUR 0.49 a year earlier, on revenue of EUR 5.76 billion versus EUR 5.66 billion. A higher quarterly profit and a lowered outlook are different signals: one describes what has been achieved, the other what is expected.
Bernstein's Ludwig also described a further reduction of Siemens' stake as a possible near-term burden on the stock, meaning the risks extend beyond operations to the ownership structure. Investors thus have two benchmarks to watch on Thursday: whether the closing quarter produces the anticipated pick-up in growth, and whether the outlook for the pressured diagnostics unit becomes more concrete. The numbers can demonstrate operating progress; commentary on diagnostics would help gauge the company's longer-term shape. Both deserve to be assessed separately from the planned stake reduction by Siemens.
Ad
Siemens Healthineers Stock: New Analysis - 3 November
Fresh Siemens Healthineers information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
